Literature DB >> 32139383

Multilevel Variation in Diabetes Screening Within an Integrated Health System.

Udoka Obinwa1, Adriana Pérez1, Ildiko Lingvay2,3, Luigi Meneghini2,4, Ethan A Halm2,3, Michael E Bowen5,3.   

Abstract

OBJECTIVE: Variation in diabetes screening in clinical practice is poorly described. We examined the interplay of patient, provider, and clinic factors explaining variation in diabetes screening within an integrated health care system in the U.S. RESEARCH DESIGN AND METHODS: We conducted a retrospective cohort study of primary care patients aged 18-64 years with two or more outpatient visits between 2010 and 2015 and no diagnosis of diabetes according to electronic health record (EHR) data. Hierarchical three-level models were used to evaluate multilevel variation in screening at the patient, provider, and clinic levels across 12 clinics. Diabetes screening was defined by a resulted gold standard screening test.
RESULTS: Of 56,818 patients, 70% completed diabetes screening with a nearly twofold variation across clinics (51-92%; P < 0.001). Of those meeting American Diabetes Association (ADA) (69%) and U.S. Preventive Services Task Force (USPSTF) (36%) screening criteria, three-quarters were screened with a nearly twofold variation across clinics (ADA 53-92%; USPSTF 49-93%). The yield of ADA and USPSTF screening was similar for diabetes (11% vs. 9%) and prediabetes (38% vs. 36%). Nearly 70% of patients not eligible for guideline-based screening were also tested. The USPSTF guideline missed more cases of diabetes (6% vs. 3%) and prediabetes (26% vs. 19%) than the ADA guideline. After adjustment for patient, provider, and clinic factors and accounting for clustering, twofold variation in screening by provider and clinic remained (median odds ratio 1.97; intraclass correlation 0.13).
CONCLUSIONS: Screening practices vary widely and are only partially explained by patient, provider, and clinic factors available in the EHR. Clinical decision support and system-level interventions are needed to optimize screening practices.
© 2020 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2020        PMID: 32139383      PMCID: PMC7171943          DOI: 10.2337/dc19-1622

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  20 in total

1.  Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement.

Authors:  Albert L Siu
Journal:  Ann Intern Med       Date:  2015-10-27       Impact factor: 25.391

2.  Performance of a Random Glucose Case-Finding Strategy to Detect Undiagnosed Diabetes.

Authors:  Michael E Bowen; Lei Xuan; Ildiko Lingvay; Ethan A Halm
Journal:  Am J Prev Med       Date:  2017-03-06       Impact factor: 5.043

3.  National patterns in diabetes screening: data from the National Health and Nutrition Examination Survey (NHANES) 2005-2012.

Authors:  Meghan M Kiefer; Julie B Silverman; Bessie A Young; Karin M Nelson
Journal:  J Gen Intern Med       Date:  2014-12-23       Impact factor: 5.128

4.  Prognostic Implications of Single-Sample Confirmatory Testing for Undiagnosed Diabetes: A Prospective Cohort Study.

Authors:  Elizabeth Selvin; Dan Wang; Kunihiro Matsushita; Morgan E Grams; Josef Coresh
Journal:  Ann Intern Med       Date:  2018-06-19       Impact factor: 25.391

5.  Changes in Screening Practices for Prediabetes and Diabetes Since the Recommendation for Hemoglobin A1c Testing.

Authors:  Joshua M Evron; William H Herman; Laura N McEwen
Journal:  Diabetes Care       Date:  2019-02-06       Impact factor: 19.112

6.  Medical care costs one year after identification of hyperglycemia below the threshold for diabetes.

Authors:  Gregory A Nichols; Bhakti Arondekar; William H Herman
Journal:  Med Care       Date:  2008-03       Impact factor: 2.983

7.  Self-reported prevalence of diabetes screening in the U.S., 2005-2010.

Authors:  Sarah Stark Casagrande; Catherine C Cowie; Saul M Genuth
Journal:  Am J Prev Med       Date:  2014-09-16       Impact factor: 5.043

Review 8.  Building Toward a Population-Based Approach to Diabetes Screening and Prevention for US Adults.

Authors:  Michael E Bowen; Julie A Schmittdiel; Jeffrey T Kullgren; Ronald T Ackermann; Matthew J O'Brien
Journal:  Curr Diab Rep       Date:  2018-09-19       Impact factor: 4.810

9.  Receipt of Glucose Testing and Performance of Two US Diabetes Screening Guidelines, 2007-2012.

Authors:  Kai McKeever Bullard; Mohammed K Ali; Giuseppina Imperatore; Linda S Geiss; Sharon H Saydah; Jeanine B Albu; Catherine C Cowie; Nancy Sohler; Ann Albright; Edward W Gregg
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

10.  Detecting Dysglycemia Using the 2015 United States Preventive Services Task Force Screening Criteria: A Cohort Analysis of Community Health Center Patients.

Authors:  Matthew J O'Brien; Ji Young Lee; Mercedes R Carnethon; Ronald T Ackermann; Maria C Vargas; Andrew Hamilton; Nivedita Mohanty; Sarah S Rittner; Jessica N Park; Amro Hassan; David R Buchanan; Lei Liu; Joseph Feinglass
Journal:  PLoS Med       Date:  2016-07-12       Impact factor: 11.069

View more
  1 in total

1.  Alternative type 2 diabetes screening tests may reduce the number of U.S. adults with undiagnosed diabetes.

Authors:  R S Dadwani; M R Skandari; M S GoodSmith; L S Phillips; M K Rhee; N Laiteerapong
Journal:  Diabet Med       Date:  2020-06-14       Impact factor: 4.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.